Simple Summary Several anti-angiogenic drugs have been approved for cancer treatment,
alone or in combination with other anti-tumoral agents. Angiogenesis inhibitors cause drug …

Simple Summary A clinical decision and study design investigating the level and extent of
angiogenesis modulation aimed at vascular normalization without rendering tissues hypoxic …

Background For patients with smoldering multiple myeloma, the standard of care is
observation until symptoms develop. However, this approach does not identify high-risk …

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma (NHL),
accounting for about 40% of all cases of NHL. Analysis of the tumor microenvironment is an …

Multiple myeloma (MM) is still an incurable disease, despite considerable improvements in
treatment strategies, as resistance to most currently available agents is not uncommon. In …

Multiple myeloma (MM) is a plasma cell neoplasm characterized by an abnormal
proliferation of clonal, terminally differentiated B lymphocytes. Current approaches for the …

In recent years, it has become increasingly apparent that bone marrow (BM) failures and
myeloid malignancy predisposition syndromes are characterized by a wide phenotypic …

Angiogenesis in metastatic castration-resistant prostate cancer (mCRPC) has been
extensively investigated as a promising druggable biological process. Nonetheless …

Simple Summary Multiple Myeloma is a hematological neoplasia originating from malignant
plasma cells in the bone marrow. Despite improved therapies, this cancer is still considered …

Despite significant advances in the understanding of multiple myeloma (MM) biology and
the development of novel treatment strategies in the last two decades, MM is still an …